|Dr. Mahesh V. Patel Ph.d.||Co-Founder, Chairman, Chief Exec. Officer and Pres||638.7k||N/A||60|
|Mr. Morgan R. Brown CPA, MBA||Chief Financial Officer, Exec. VP and Corp. Sec.||420.24k||N/A||49|
|Dr. William I. Higuchi Ph.D.||Chief Scientific Consultant||N/A||N/A||86|
|Mr. Gregory B. Bass||Chief Commercial Officer and Exec. VP||N/A||N/A||43|
Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of mens and womens health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The companys pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Lipocine Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.